(NASDAQ: VCYT) Veracyte's forecast annual revenue growth rate of 8.74% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.81%.
Veracyte's revenue in 2025 is $495,141,000.On average, 15 Wall Street analysts forecast VCYT's revenue for 2025 to be $40,882,651,292, with the lowest VCYT revenue forecast at $38,775,200,340, and the highest VCYT revenue forecast at $42,250,992,477. On average, 15 Wall Street analysts forecast VCYT's revenue for 2026 to be $45,272,251,869, with the lowest VCYT revenue forecast at $41,955,348,570, and the highest VCYT revenue forecast at $47,310,930,041.
In 2027, VCYT is forecast to generate $50,481,592,370 in revenue, with the lowest revenue forecast at $45,295,176,129 and the highest revenue forecast at $53,305,228,829.